OOIR: Observatory of International Research

Papers

(The H4-Index of Diabetes Obesity & Metabolism is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
	548
Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study	237
	208
Diabetes, Obesity and Metabolism	125
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”	123
Effects of CB1R inverse agonist, INV‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study	122
GLP‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity	100
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes	92
Front Cover	90
Long‐term effects of metformin on offspring health: A review of current evidence and future directions	88
Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy	88
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia	86
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c	79
The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?	78
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes	78
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes	77
Issue Information	76
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover	74
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status	74
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis	73
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin	72
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes	72
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease	68
Adaptive bolus calculators for people with type 1 diabetes: A systematic review	66
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump	63

Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’	63
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial	56
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry	54
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh	53
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial	51
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa	51
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity	51
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study	51
Continuous glucose monitoring and all‐cause mortality in insulin‐using population with diabetes and cognitive impairment	50
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy	49
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors	47
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial	47
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial	47
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups	47
The benefit of dexamethasone in patients with COVID‐19 infection is preserved in patients with diabetes	47
Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020	46
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III	46
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis	45
Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study	45
Incidence of chronic kidney disease among adults with prediabetes in the CURE‐CKD registry, 2013–2020	45